Small- and mid-cap stocks (SMID), despite bursts of outperformance, have underperformed large-caps year to date - as they have over the past five years. But they may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from unrest in the Middle East, the Russian invasion of Ukraine, issues in China, or other geopolitical developments. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky, but despite those risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 20% of the U.S. stock market's capitalization is comprised of SMID stocks.

Quest Diagnostics is a provider of clinical diagnostic services that help to identify and treat disease and improve healthcare management. Quest is based in Secaucus, New Jersey; the stock is a component of the S&P 500.

Monday Tee Up: Fed, Jobs, Earnings This week features more earnings from corporate giants, key jobs data, and a Fed rate meeting. It doesn't get much busier than that, especially for a week in the heat of summer. But spoiler alert on the Fed: no one thinks a rate move is coming this week and odds are at zero. Last week, the markets were again volatile. The Dow Jones Industrial Average ended up 0.8%, the S&P 500 lost 0.8%, and the Nasdaq fell 2.1%. Year to date, the DJIA is higher by nearly 8%, the S&P is up 14%, and the Nasdaq is higher by 15%. On the economic calendar, the Federal Reserve rate decision comes on Wednesday and economists expect no movement. As usual, analysts will dissect what Chairman Powell says in the press conference. Odds are high for a rate cut in September, so Wall Street will be looking for verification that the Fed is leaning in that direction. On Friday, the important July jobs report is due. In June, Nonfarm Payrolls came in at 206,000. Argus sees that declining to 185,000 for July. The unemployment rate was 4.1% in June. We expect no change for July. Meanwhile, Job Openings, Consumer Confidence, and the Case-Shiller Home Price Index will be reported on Tuesday. On Wednesday, the ADP Private Employment report is due out, and on Thursday, ISM Manufacturing and Construction Spending hit the tape. On the earnings calendar, Monday brings news from McDonald's. On Tuesday, Microsoft, Advanced Micro Devices, Procter & Gamble, Pfizer, Merck, and Starbucks report; on Wednesday, Meta, Qualcomm, Boeing, Altria, and Kraft Heinz; on Thursday, Apple, Amazon, Moderna, Booking Holdings, and Coinbase; and on Friday, Chevron and Exxon Mobil. Earnings so far have been coming in 12.1% higher this quarter than a year ago, and 41% of S&P 500 companies have reported. Expectations are for earnings growth of 8%-12% for 2Q. This follows 8% growth in 1Q and 10% in 4Q23. At Argus, we expect EPS for all of 2024 to come in roughly 8%-9% better than last year. Last week featured good news on inflation and economic growth. The Personal Consumption Expenditures Index showed that inflation slowed to 2.5% in June versus 2.6% in May. Core PCE didn't budge, sticking at 2.6%. The initial reading for second-quarter GDP came in at 2.8%, a big jump from 1.4% in 1Q. Mortgage rates ticked up a hair to 6.78% for the average 30-year fixed-rate mortgage. Gas prices fell 3 cents to $3.47 per gallon for the average price of regular gas. The Atlanta Fed GDPNow indicator is forecasting for 3Q and calls for expansion of 2.8%. The Cleveland Fed CPINow indicator forecasts 3.01% for CPI in July. After this week's Fed rate decision, the next one is in mid-September -- and odds at 99% for a cut at that meeting. Of that, 88% expect a 25-basis-point (BPS) cut, while 11% expect a 50 bps cut. As the probability is so high for a rate cut at the September meeting, odds are at 68% for a second cut in November, but a higher 98% for that second cut to take place on December 18. All of this data is according to the CME FedWatch Tool.

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.